Establishing a stem cell culture laboratory for clinical trials
Carregando...
Citações na Scopus
15
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
Associação Brasileira de Hematologia e Hemoterapia e da
Autores
SEKIYA, Elíseo Joji
FORTE, Andresa
KüHN, Telma Ingrid Borges de Bellis
JANZ, Felipe
ALVES, Adelson
Citação
REVISTA BRASILEIRA DE HEMATOLOGIA E HEMOTERAPIA, v.34, n.3, p.236-241, 2012
Resumo
Adult stem/progenitor cells are found in different human tissues. An in vitro cell culture is needed for their isolation or for their expansion when they are not available in a sufficient quantity to regenerate damaged organs and tissues. The level of complexity of these new technologies requires adequate facilities, qualified personnel with experience in cell culture techniques, assessment of quality and clear protocols for cell production. The rules for the implementation of cell therapy centers involve national and international standards of good manufacturing practices. However, such standards are not uniform, reflecting the diversity of technical and scientific development. Here standards from the United States, the European Union and Brazil are analyzed. Moreover, practical solutions encountered for the implementation of a cell therapy center appropriate for the preparation and supply of cultured cells for clinical studies are described. Development stages involved the planning and preparation of the project, the construction of the facility, standardization of laboratory procedures and development of systems to prevent cross contamination. Combining the theoretical knowledge of research centers involved in the study of cells with the practical experience of blood therapy services that manage structures for cell transplantation is presented as the best potential for synergy to meet the demands to implement cell therapy centers.
Palavras-chave
Stem cells, Tissue therapy, Cell culture techniques, Good manufacturing practices
Referências
- Areman EM, 2009, Cellular therapy: principles, methods, and regulations
- Brasil, 2011, Resolução - RDC n.9, de 14 de março de. Dispõe sobre o funcionamento dos Centros de Tecnologia Celular para fins de pesquisa clínica e terapia e dá outras providências
- Brasil, 2002, Resolução RDC nº 50 de 21 de fevereiro de 2002: Dispõe sobre o Regulamento Técnico para planejamento, programação, elaboração e avaliação de projetos físicos de estabelecimentos assistenciais de saúde
- Brasil, 2010, Resolução -RDC nº 56, de 16 de dezembro de 2010: Dispõe sobre o regulamento técnico para o funcionamento dos laboratórios de processamento de células progenitoras hematopoéticas (CPH) provenientes de medula óssea e sangue periférico e bancos de sangue de cordão umbilical e placentário, para finalidade de transplante convencional e dá outras providências
- Brasil, 2010, Resolução -RDC nº 57, de 16 de dezembro de 2010: Determina o Regulamento Sanitário para serviços que desenvolvem atividades relacionadas ao ciclo produtivo do sangue humano e seus componentes e procedimentos transfusionais
- Broxmeyer HE, 2003, P NATL ACAD SCI USA, V100, P645, DOI 10.1073/pnas.0237086100
- Burger SR, 2000, CYTOTHERAPY, V2, P111, DOI 10.1080/146532400539116
- Coutinho LH, 1999, Prog Clin Biol Res, V333, P415
- European Medicines Agency, Quality of biotechnological products: viral safety evaluation of biotechnology product derived from cell lines in of human or animal origin
- European Medicines Agency, 1998, Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products
- European Medicines Agency, Quality of biotechnological products: Derivation and characterisation of cell substrates used for production of biotechnological/biological products
- Food and Drug Administration, 2007, Fed Regist, V72
- Gastineau DA, 2004, BONE MARROW TRANSPL, V33, P777, DOI 10.1038/sj.bmt.1704452
- Harvath L, 2000, TRANSFUS MED REV, V14, P104, DOI 10.1016/S0887-7963(00)80002-4
- International Organization for Standardization, 2005, Biological evaluation of medical devices- Part 18: Chemical characterization of materials
- International Organization for Standardization, 2006, Biological evaluation of medical devices- Part 19: Physico-chemical, morphological and topographical characterization of materials
- International Organization for Standardization, 1999, Cleanrooms and associated controlled environments-Part 1: Classification of air cleanliness
- International Organization for Standardization, 2009, Biological evaluation of medical devices -Part 1: Evaluation and testing within a risk management process
- Mannello F, 2007, STEM CELLS, V25, P1603, DOI 10.1634/stemcells.2007-0127
- Rous P, 1916, J EXP MED, V23, P549, DOI 10.1084/jem.23.4.549
- Schallmoser K, 2007, TRANSFUSION, V47, P1436, DOI 10.1111/j.1537-2995.2007.01220.x
- SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695
- Sensebe L, 2008, BIO-MED MATER ENG, V18, P173, DOI 10.3233/BME-2008-0520
- The Commission of the European Communities, Directive 2001/83/ EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use
- The Commission of the European Communities, 2004, Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells
- The Commission of the European Communities, 2003, Commission Directive 2003/63/CE: Community code relating to medicinal products for human use
- The Commission of the European Communities, Commissions Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells. Official Journal of the European Union
- The European Agency for the Evaluation of Medicinal Products, 2002, Note for guidance on use of bovine serum in the manufacture of human biological medicinal product
- The European Agency for the Evaluation of Medicinal Products, 2002, Points to consider on xenogeneic cell therapy medicinal products
- The European Agency for the Evaluation of Medicinal Products, 2007, Committee for human medicinal product (CHMP): Guideline on human cell-based medicinal products
- The European Agency for the Evaluation of Medicinal Products, 2003, Note for guidance on minimizing the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMEA/410/01 rev.2- October 2003
- The European Agency for the Evaluation of Medicinal Products, 2001, Note for guidance on the quality, preclinical and clinical aspects of gene transfer medicinal products
- The European Agency for the Evaluation of Medicinal Products, 2001, Note for guidance on plasma-derived medicinal products
- U.S. Food and Drug Administration, 1997, Fed Regist, V62, P40429
- U.S. Food and Drug Administration, 1996, Guidance on applications for products comprised of living autologous cells manipulated ex vivo and intended for structural repair or reconstruction
- U.S. Food and Drug Administration, 2004, Guidance for industry: Sterile drug products produced by aseptic processing -current good manufacturing practice
- U.S. Food and Drug Administration, CFR- Code of Federal Regulations Title 21: Human cells, tissues, and cellular and tissue-based products. Part 1271
- US Food and Drug Administration, 2004, FED REGISTER, V69, P29785
- U.S. Food and Drug Administration, 2008, CFR-Code of Federal Regulations Title 21: Current good manufacturing practice for finished pharmaceuticals Part 211
- U.S. Food and Drug Administration, 2007, Guidance for industry: regulation of human cells, tissues, and cellular and tissue-based products (HCT/Ps), small entity compliance guide
- Wagner JE, 2004, EXP HEMATOL, V32, P412, DOI 10.1016/j.exphem.2004.03.009
- Weber D. J., 2004, BIOPROCESSING INT, V2, P22
- Whiteside TL, 2011, CYTOTHERAPY, V13, P201, DOI 10.3109/14653249.2010.506507